S

Sesen Bio Inc
F:PCBK

Watchlist Manager
Sesen Bio Inc
F:PCBK
Watchlist
Price: 0.5124 EUR 28.1% Market Closed
Market Cap: 103.9m EUR

Operating Margin
Sesen Bio Inc

34.1%
Current
-15%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
34.1%
=
Operating Profit
13.6m
/
Revenue
40m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Sesen Bio Inc
F:PCBK
103.9m EUR
34%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
407.1B USD
33%
US
Amgen Inc
NASDAQ:AMGN
179.3B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
157.2B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.6B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD
28%
AU
CSL Ltd
ASX:CSL
85.1B AUD
26%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.5B USD
8%
NL
argenx SE
XBRU:ARGX
44.2B EUR
22%
No Stocks Found

Sesen Bio Inc
Glance View

Market Cap
103.9m EUR
Industry
Biotechnology

Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 35 full-time employees. The company went IPO on 2014-02-06. The firm's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process. The Company’s advanced product candidate Vicinium, also known as VB4-845, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus calmette-guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).

PCBK Intrinsic Value
Not Available
S
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
34.1%
=
Operating Profit
13.6m
/
Revenue
40m
What is the Operating Margin of Sesen Bio Inc?

Based on Sesen Bio Inc's most recent financial statements, the company has Operating Margin of 34.1%.

Back to Top